Neurocrine Biosciences (NBIX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $17.67B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Kyle W. Gano |
| IPO Date | 1996-05-23 | CAGR | 18.83% |
| Employees | 2,000 | Website | www.neurocrine.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.1% | Total Yield | 0.1% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $15.30B | P/E | 25.4 | Forward P/E | 13.88 | PEG | 0.01 |
| P/S | 43.89 | P/B | 39.97 | P/CF | 157.82 | P/FCF | 164 |
| Sales | $3.10B | Sales 1Y | 28.59% | Sales 3Y | 94.08% | Sales 5Y | 196.77% |
| EPS | $6.92 | EPS 1Y | 120% | EPS 3Y | 981.67% | EPS 5Y | 58.29% |
| Sales QoQ | 1.12% | EPS QoQ | 29.05% | Sales QoQ Avg | 9.53% | EPS QoQ Avg | 329.76% |
| Gross Margin | 98.17% | Operating Margin | 25.19% | Profit Margin | 21.55% | ROCE | 19.18% |
| ROA | 14% | ROE | 22% | Altman Z Score | 8.84 | Piotroski Score | 5 |
| Current Ratio | 2.93 | Quick Ratio | 2.85 | Cash Ratio | 0.32 | Op. CF Ratio | 0.18 |
| Debt/Equity | 0.12 | Debt/Assets | 0.08 | Lt Debt/Equity | 0.12 | Lt Debt/Cap. | 0.11 |
| Intrst Cov. | — | Inventory Turnover | 0.88 | Asset Turnover | 0.63 | Receivables Turnover | 4.04 |
| Enterprise Value | $15.30B | P/E Ratio | 25.4 |
| Forward P/E | 13.88 | PEG Ratio | 0.01 |
| P/S Ratio | 43.89 | P/B Ratio | 39.97 |
| P/CF Ratio | 157.82 | P/FCF Ratio | 164 |
| EPS | $6.92 | EPS Growth 1Y | 120% |
| EPS Growth 3Y | 981.67% | EPS Growth 5Y | 58.29% |
| Revenue Growth 1Y | 28.59% | Gross Margin | 0.98% |
| Operating Margin | 0.25% | Profit Margin | 0.22% |
| ROE | 0.22% | ROA | 0.14% |
| ROCE | 0.19% | Current Ratio | 2.93 |
| Quick Ratio | 2.85 | Cash Ratio | 0.32 |
| Debt/Equity | 0.12 | Interest Coverage | — |
| Altman Z Score | 8.84 | Piotroski Score | 5 |
Neurocrine Biosciences (NBIX) valuation & financials
Neurocrine Biosciences (NBIX) has a market capitalization of $17.67B and trades at a price-to-earnings ratio of 25.4. It operates in the Healthcare sector (Biotechnology).
Neurocrine Biosciences's revenue grew +28.6% over the last year.
Neurocrine Biosciences's next earnings report is scheduled for July 30, 2026; analysts estimate EPS of $2.19.
Neurocrine Biosciences (NBIX) — frequently asked questions
When does Neurocrine Biosciences (NBIX) report earnings next?
Neurocrine Biosciences is expected to report earnings on July 30, 2026. Analysts estimate EPS of $2.19.
What is Neurocrine Biosciences's market cap?
Neurocrine Biosciences (NBIX) has a market capitalization of $17.67B.
What is NBIX's P/E ratio?
Neurocrine Biosciences trades at a price-to-earnings ratio of 25.4, with trailing twelve-month EPS of $6.92.
How fast is Neurocrine Biosciences growing?
Neurocrine Biosciences's revenue grew +28.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)